Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Pfizer India has announced its 4QFY15 results. The company has reported an 81.3% YoY growth in net sales and a decline of 23.8% YoY in net profits. Here is our analysis of the results.
(Rs m) | 4QFY14 | 4QFY15 | Change | FY14 | FY15 | Change |
Net sales | 2,517 | 4,563 | 81.3% | 10,043 | 18,277 | 82.0% |
Other operating income | 228 | 68 | -70.2% | 1,075 | 256 | -76.2% |
Expenditure | 2,016 | 3,383 | 67.8% | 8,733 | 14,703 | 68.4% |
Operating profit (EBDITA) | 729 | 1,248 | 71.1% | 2,385 | 3,830 | 60.6% |
EBDITA margin (%) | 26.6% | 26.9% | 21.5% | 20.7% | ||
Other income | 163 | 188 | 15.1% | 1,094 | 674 | -38.4% |
Interest (net) | 1.9 | 1.7 | -10.5% | 4 | 8 | 113.9% |
Depreciation | 20 | 336 | 1557.1% | 80 | 1,311 | |
Profit before tax | 870 | 1,097 | 26.1% | 3,396 | 3,185 | -6.2% |
Exceptional Item | - | - | - | (804) | ||
Tax | 310 | 671 | 116.5% | 1,188 | 1,377 | 15.9% |
Profit after tax/(loss) | 560 | 427 | -23.8% | 2,208 | 1,004 | -54.5% |
Net profit margin (%) | 20.4% | 9.2% | 22.0% | 5.5% | ||
No. of shares (m) | 29.8 | 29.8 | ||||
Diluted earnings per share (Rs) | 34.8 | |||||
Price to earnings ratio (x)* | 60.8 |
| |
DISCLOSURES UNDER SEBI (RESEARCH ANALYSTS) REGULATIONS, 2014
|
INTRODUCTION:
Equitymaster Agora Research Private Limited (hereinafter referred to as "Equitymaster"/"Company") was incorporated on October 25, 2007. Equitymaster is a joint venture between Quantum Information Services Private Limited (QIS) and Agora group. Equitymaster is a SEBI registered Research Analyst under the SEBI (Research Analysts) Regulations, 2014 with registration number INH000000537. BUSINESS ACTIVITY: An independent research initiative, Equitymaster is committed to providing honest and unbiased views, opinions and recommendations on various investment opportunities across asset classes. DISCIPLINARY HISTORY: There are no outstanding litigations against the Company, it subsidiaries and its Directors. GENERAL TERMS AND CONDITIONS FOR RESEARCH REPORT: For the terms and conditions for research reports click here. DETAILS OF ASSOCIATES: Details of Associates are available here. DISCLOSURE WITH REGARDS TO OWNERSHIP AND MATERIAL CONFLICTS OF INTEREST:
If you have any feedback or query or wish to report a matter, please do not hesitate to write to us. |